0RQE Stock Chart & Stats
CHF5.34
CHF0.47(7.54%)
At close: 4:00 PM EDT
CHF5.34
CHF0.47(7.54%)
Day’s Range― - ―
52-Week RangeCHF2.82 - CHF7.55
Previous CloseN/A
Volume312.22K
Average Volume (3M)216.89K
Market Cap
CHF1.34B
Enterprise ValueCHF3.01K
Total Cash (Recent Filing)CHF88.69M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding269,055,730
10 Day Avg. Volume184,421
30 Day Avg. Volume216,886
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.50Price Target Upside-15.73% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.57
Revenue Forecast (FY)CHF216.54M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelIdorsia combines commercial product sales with partnership-based licensing, milestones, royalties, and cost-sharing income. This diversified model can broaden monetization routes across products and territories, while reducing reliance on a single medicine or commercialization channel over the medium term.
Broad Clinical PipelineA pipeline spanning several therapeutic areas gives Idorsia multiple opportunities to create future value through approvals, launches, or partnerships. Broader development exposure can support longer-term growth if clinical candidates progress and complement its existing commercial medicines.
Strong Gross MarginAn approximately 81% gross margin indicates that Idorsia’s products generate substantial gross profit before operating expenses. If maintained, this product-level economics provides a foundation for improving operating leverage as commercial scale increases or development spending becomes more selective.
Bears Say
Weak Revenue And ProfitabilityFalling TTM revenue alongside EBIT, EBITDA, and net margins near -99%, -91%, and -158% shows that current commercial scale is not covering the company’s cost base. Persistent operating losses can restrict reinvestment capacity and make sustained improvement dependent on revenue recovery or cost reductions.
Stressed Balance SheetMaterially negative equity and debt that is large relative to the reported asset base create a highly constrained financial position. This reduces flexibility to fund pipeline development, absorb setbacks, or pursue strategic opportunities without continued reliance on external financing or restructuring actions.
Ongoing Cash BurnNegative operating and free cash flow demonstrate that Idorsia is consuming cash rather than internally funding its operations and development activities. Further deterioration in free cash flow would increase the need for ongoing funding and could limit the company’s ability to control the timing of investment.
0RQE FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest share price was CHF2.81 and its highest was CHF7.55 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.34B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 51 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.165 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.03.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.27.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,055,730 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.165 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -5.64%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in GB:0RQE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
0RQE Stock 12 Month Forecast
Average Price Target
CHF4.50
▼(-15.73% Downside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―